The modern view of lymphangioleiomyomatosis: etiology, pathogenesis, clinical features, diagnosis and treatment

Cover Page

Cite item

Full Text

Abstract

The article presents a contemporary view of lymphangioleiomyomatosis, and is devoted to the main etiology, pathogenesis, clinical manifestations and treatment of disease.

About the authors

M. A Makarova

Insitute of pulmonology; City Clinical Hospital №57 of the Department of Health of Moscow

Email: mma123@list.ru
канд. мед. наук, науч. сотр. лаб. интенсивной терапии и дыхательной недостаточности ФГБУ НИИ пульмонологии, ГБУЗ ГКБ №57 105077, Россия, Москва, ул. 11-я Парковая, д. 32, корп. 4

S. N Avdeev

Insitute of pulmonology; City Clinical Hospital №57 of the Department of Health of Moscow

Email: serg_avdeev@list.ru
д-р мед. наук, проф., рук. клин. отд. ФГБУ НИИ пульмонологии, ГБУЗ ГКБ №57 105077, Россия, Москва, ул. 11-я Парковая, д. 32, корп. 4

Z. M Merzhoeva

Insitute of pulmonology

Email: Zamira.merzhoeva@bk.ru
канд. мед. наук, науч. сотр. лаб. интенсивной терапии и дыхательной недостаточности ФГБУ НИИ пульмонологии 105007, Russian Federation, Moscow, ul. 11-ia Parkovaia, d. 32, korp. 4

References

  1. Meraj R, Wikenheiser-Brokamp K.A, Young L.R et al. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012; 33: 486-97.
  2. Ando K, Tobino K, Kurihara M et al. Quantitative CT analysis of small pulmonary vessels in lymphangioleiomyomatosis. Eur J Radiol 2012; 81: 3925-30.
  3. Johnson S.R, Cordier J.F, Lazor R et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35: 14-26.
  4. Mc Cormack F.X. Lymphangioleiomyomatosis: a clinical update. Chest 2008; 133: 507.
  5. Taylor J.R, Ryu J, Colby T.V et al. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323: 1254-60.
  6. Kitaichi M, Nishimura K, Itoh H et al. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151: 527-33.
  7. Urban T, Lazor R, Lacronique J et al. Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine (Baltimore) 1999; 78: 321-37.
  8. Sieker H.O, Jr Mc Carty K.S. Lymphangiomyomatosis: a respiratory illness with an endocrinologic therapy. Trans Am Clin Climatol Assoc 1987; 99: 57-67.
  9. Franz D.N, Brody A, Meyer C et al: Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164: 661-8.
  10. Costello L.C, Hartman T.E, Ryu J.H. High frequency of pulmonary lymphangioleiomyomatosis in women with tuberous sclerosis complex. Mayo Clin Proc 2000; 75: 591-4.
  11. Moss J, Avila N.A, Barnes P.M et al. Prevalence and clinical characteristics of lymphangioleiomyomatosis (LAM) in patients with tuberous sclerosis complex. Am J Respir Crit Care Med 2001; 164: 669-71.
  12. Astrinidis A, Henske E.P. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease. Oncogene 2005; 24: 7475-81.
  13. Cornog J.L.Jr, Enterline H.T. Lymphangiomyoma, a benign lesion of chyliferous lymphatics synonymous with lymphangiopericytoma. Cancer 1966; 19: 1909-30.
  14. Stovin P.G, Lum L.C, Flower C.D et al: The lungs in lymphangiomyomatosis and in tuberous sclerosis. Thorax 1975; 30: 497-509.
  15. Kwiatkowski D.J, Reeve M.P, Cheadle J.P, Sampson J.R. Molecular Genetics. In: Nuberous Sclerosis complex: from Basic Science to Clinical Phenotypes. Ed: P.Curatolo. London: Mac Keith Press, 2003; p. 228-63.
  16. Astrinidis A, Khare L, Carsillo T et al. Mutational analysis of the tuberous sclerosis gene TSC2 in patients with pulmonary lymphangioleiomyomatosis. J Med Genet 2000; 37: 55-7.
  17. Franz D.N, Brody A, Meyer C et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med 2001; 164: 661-8.
  18. Jones A.C, Shyamsundar M.M, Thomas M.W et al. Comprehensive mutation analysis of TSC1 and TSC2 and phenotypic correlations in 150 families with tuberous sclerosis. Am J Hum Genet 1999; 64: 1305-15.
  19. Harari S et al. Lymphangioleiomyomatosis: what do we know and what are we looking for? Eur Respir Rev 2011; 20 (119): 34.
  20. Juvet S.C, Mc Cormack F.X, Kwiatkowski D.J et al. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2007; 36: 398-408.
  21. Taveira-Da-Silva A.M, Moss J. Progress in the treatment of lymphangioleiomyomatosis: from bench to bedside. Rev Port Pneumol 2012; 18: 142-4.
  22. Taylor J.R, Ryu J, Colby T.V et al: Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323: 1254-60.
  23. Kim N.R, Chung M.P, Park C.K et al. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int 2003; 53: 231-5.
  24. Cudzilo C.J, Szczesniak R.D, Brody A.S et al. Lymphangioleiomyomatosis screening in women with tuberous sclerosis. Chest 2013.
  25. Johnson S.R, Tattersfield A.E. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-7.
  26. Almoosa K.F, Ryu J.H, Mendez J et al. Management of pneumothorax in lymphangioleiomyomatosis: effects on recurrence and lung transplantation complications. Chest 2006; 129: 1274-81.
  27. Moua T, Olson E.J, St Jean H.C et al. Resolution of chylous pulmonarycongestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186: 389-90.
  28. Chu S.C, Horiba K, Usuki J et al. Comprehensive evaluation of 35 patients with lymphangioleiomyomatosis. Chest 1999; 115: 1041-52.
  29. Sullivan E.J. Lymphangioleiomyomatosis: a review. Chest 1998; 114: 1689-703.
  30. Young L.R, Vandyke R, Gulleman P.M et al. Serum vascular endothelial growth factor - d prospectively distinguishes lymphangioleiomyomatosis from other diseases. Chest 2010; 138: 674-81.
  31. Jr Guinee D.G, Feuerstein I, Koss M.N et al. Pulmonary lymphangioleiomyomatosis. Diagnosis based on results of transbronchial biopsy and immunohistochemical studies and correlation with highresolution computed tomography findings. Arch Pathol Lab Med 1994; 118: 846-9.
  32. Meraj R, Wikenheiser-Brokamp K.A, Young L.R et al. Utility of transbronchial biopsy in the diagnosis of lymphangioleiomyomatosis. Front Med 2012; 6: 395-405.
  33. Harari S, Torre O, Cassandro R et al. Bronchoscopic diagnosis of Langerhans cell histiocytosis and lymphangioleiomyomatosis. Respir Med 2012; 106: 1286-92.
  34. Ye L, Jin M, Bai C. Clinical analysis of patients with pulmonary lymphangioleiomyomatosis (PLAM) in mainland china. Respir Med 2010; 104: 1521-6.
  35. Hughes E, Hodder R.V. Pulmonary lymphangiomyomatosis complicating pregnancy. A case report. J Reprod Med 1987; 32: 553-7.
  36. Yockey C.C, Riepe R.E, Ryan K. Pulmonary lymphangioleiomyomatosis complicated by pregnancy. Kans Med 1986; 87: 277-8, 293.
  37. Sleiman C, Mal H, Jebrak G et al. Pulmonary lymphangiomyomatosis treated by single lung transplantation. Am Rev Respir Dis 1992; 145: 964-6.
  38. Kerr L.A, Blute M.L, Ryu J.H et al. Renal angiomyolipoma in association with pulmonary lymphangioleiomyomatosis: forme fruste of tuberous sclerosis? Urology 1993; 41: 440-4.
  39. Johnson S.R, Tattersfield A.E. Pregnancy in lymphangioleiomyomatosis. Am J Respir Crit Care Med 1998; 157: A807.
  40. Johnson S.R, Tattersfield A.E. Clinical experience of lymphangioleiomyomatosis in the UK. Thorax 2000; 55: 1052-7.
  41. Shen A, Iseman M.D, Waldron J.A et al: Exacerbation of pulmonary lymphangioleiomyomatosis by exogenous estrogens. Chest 1987; 91: 782-5.
  42. Kim N.R, Chung M.P, Park C.K et al. Pulmonary lymphangioleiomyomatosis and multiple hepatic angiomyolipomas in a man. Pathol Int 2003; 53: 231-5.
  43. Juvet S.C, Mc Cormack F.X, Kwiatkowski D.J et al. Molecular pathogenesis of lymphangioleiomyomatosis: lessons learned from orphans. Am J Respir Cell Mol Biol 2007; 36: 398-408.
  44. Cordier J.F, Johnson S.R. Orphan Lung Diseases. Ed. By J.F.Cordier. Eur Respir Mon 2011; 54: 46-83
  45. Taveira-Da-Silva A.M, Hathaway O, Stylianou M et al. Changes in lung function and - chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154: 797-805, W-292-3.
  46. Katsutoshi A, Masatoshi K, Hideyuki K et al. The efficacy and safetyoflow - dosesirolimusfor treatment oflymphangioleiomyomatosis. Respir Investig 2013; 51: 175-83.
  47. Nine J.S, Yousem S.A, Paradis I.L et al. Lymphangioleiomyomatosis: recurrence after lung transplantation. J Heart Lung Transplant 1994; 13: 714-9.
  48. O’Brien J.D, Lium J.H, Parosa J.F et al. Lymphangioleiomyomatosis recurrence in the allograft after single lung transplantation. Am J Respir Crit Care 1995; 151: 2033-6.
  49. Bittmann I, Rolf B, Amann G et al. Recurrence of lymphangioleiomyomatosis after single lung transplantation: new insights into pathogenesis. Hum Pathol 2003; 34: 95-8.
  50. Karbowniczek M, Astrinidis A, Balsara B.R et al. Recurrent lymphangiomyomatosis after transplantation: genetic analyses reveal a metastatic mechanism. Am J Respir Crit Care Med 2003; 167: 976-82.
  51. Orens J.B, Estenne M, Arcasoy S et al. International guidelines for the selection of lung transplant candidates: 2006 update - a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25: 745-55.
  52. Taveira-Da-Silva A.M, Steagall W.K, Moss J. Lymphangioleiomyomatosis. Cancer Control 2006; 13: 276-85.
  53. Lazor R, Valeyre D, Lacronique J et al. Low initial KCO predicts rapid FEV1 decline in pulmonary lymphangioleiomyomatosis. Respir Med 2004; 98: 536-41.
  54. Johnson S.R, Tattersfield A.E. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160: 628-33.
  55. Hayashida M, Seyama K, Inoue Y et al. The epidemiology of lymphangioleiomyomatosis in Japan: a nationwide cross - sectional study of presenting features and prognostic factors. Respirology 2007; 12: 523-30.
  56. Matsui K, Beasley M.B, Nelson W.K et al. Prognostic significance of pulmonary lymphangioleiomyomatosis histologic score. Am J Surg Pathol 2001; 25: 479-84.
  57. Oprescu N, Mc Cormack F.X, Byrnes S et al. Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population - based registry. Lung 2013; 191: 35-42.

Copyright (c) 2015 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies